Clinical Trials
Diffusion completes enrolling brain cancer patients in TSC Phase II trial
Diffusion Pharmaceuticals has completed enrolling 56 patients with newly diagnosed primary brain cancer (glioblastoma multiforme or GBM) in the Phase II trial of an anti-cancer compound, trans sodium crocetinate (TSC). Patients were enrolled at...
Clinical Trials
Boston Therapeutics presents PAZ320 drug positive Phase ll results
Boston Therapeutics has presented positive results of its PAZ320 drug, designed for reducing post-meal elevation of blood glucose, from its Phase ll clinical trial. Non-systemic chewable complex carbohydrate-based drug is a proprietary polysaccharide which...
Clinical Trials
Avaxia treats first patient in ulcerative colitis drug study
Avaxia Biologics has treated the first patient in a Phase1b clinical study using AVX drug dosage, designed for the treatment of ulcerative colitis. The gut-targeted anti-TNF antibody drug is injected into the body to...
Clinical Trials
CSL Behring begins pediatric Phase III hemophilia B study of rIX-FP
CSL Behring has commenced the patient enrollment in pivotal pediatric Phase III hemophilia B study of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The study is designed to assess rIX-FP's...
Clinical Trials
GlycoMimetics completes enrollment in Phase 2 study of GMI-1070
Clinical-stage biotechnology company GlycoMimetics has completed patient enrollment for the Phase 2 sickle cell disease study evaluating GMI-1070. Hospitalized sickle cell disease patients experiencing vaso-occlusive crisis were examined for the efficacy, safety and pharmacokinetics...
Clinical Trials
Kiadis Pharma raises fund for Phase II study of ATIR
Kiadis Pharma has raised EUR10m in a financing round to conduct Phase II study of a cell based medicinal product candidate, ATIR, and to prepare a Phase II/III study. ATIR Phase II study is...
Clinical Trials
Pfizer Phase 3 fibromyalgia study of pregabalin meets primary endpoint
Pfizer Phase III study of pregabalin controlled-release (CR) formulation has met primary endpoint of time to loss of therapeutic response (LTR), in fibromyalgia patients. The primary endpoint of the placebo-controlled, multi-center study was achieved...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
